coagulation factor II, thrombin
Zuletzt aktualisiert 14. Jan 2025
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Ask Patient
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
The F2 gene provides instructions for making a protein called prothrombin (also known as coagulation factor II). Coagulation factors are a group of related proteins that are essential for normal blood clotting (hemostasis). After an injury, clots protect the body by sealing off damaged blood vessels and preventing further blood loss.
Normal function
The F2 gene provides instructions for making a protein called prothrombin (also known as coagulation factor II). Coagulation factors are a group of related proteins that are essential for normal blood clotting (hemostasis). After an injury, clots protect the body by sealing off damaged blood vessels and preventing further blood loss.
Prothrombin is made chiefly by cells in the liver. The protein circulates in the bloodstream in an inactive form until an injury damages blood vessels. In response to the injury, prothrombin is converted to its active form, thrombin. Thrombin then converts a protein called fibrinogen into fibrin, the primary protein that makes up blood clots.
Thrombin is also thought to be involved in cell growth and division (proliferation), tissue repair, and the formation of new blood vessels (angiogenesis).
Conditions referring to this gene or chromosome
Other names
coagulation factor II
coagulation factor II (thrombin)
PT
RPRGL2
THPH1
Related patient information and medicines

Patient information leaflet
Thrombophilie
The body has a natural clotting process in the blood, which is altered in thrombophilia. What is thrombophilia. Thrombophilia refers to a group of conditions where the blood clots more easily than normal. This can lead to unwanted blood clots (called thromboses) forming within blood vessels. Prothrombin 20210 Prothrombin ist a clotting factor, and.

Patient information leaflet
Antikoagulantien
Dabigatran Dabigatran , apixaban Apixaban tablets , edoxaban Edoxaban tablets and rivaroxaban Rivaroxaban tablets prevent a blood chemical called thrombin from working. These activated platelets and the damaged tissue release chemicals which react with other chemicals and proteins i... There are 13 known clotting factors which are called by their.

Patient information leaflet
Antiphospholipid-Syndrom
It is a disease that affects the blood and makes it more likely to clot than normal - a thrombophilia. Antiphospholipid syndrome (APS) - also called Hughes' syndrome - makes blood more likely than normal to clot (a thrombophilia Thrombophilia ). This increases the risk of developing blood clots (called thromboses) within blood vessels. APS can.

Patient information leaflet
Blutgerinnungstests
Blutgerinnungstests are used to diagnose and assess bleeding problems and to monitor people who take Warfarin or other Antikoagulans medicines. You may be advised to have blood clotting tests: If you have a suspected bleeding disorder. For example, if you bleed a lot after cuts, or if you bruise easily. If you have certain liver diseases that can.

Patient information leaflet
Schlaganfall
Behinderung following a Schlaganfall depends on factors such as the part of the Gehirn affected, how quickly treatment was given and the extent of the damage to the brain. Forn more information on strokes, go to [/health/stroke-leaflet](https://patient.info/health/stroke-leaflet) A stroke means that the blood supply to a part of the.

Patient information leaflet
Hämorrhoiden
Piles (haemorrhoids) are swollen lumps in or around the bottom that cause discomfort, itching, or bleeding. Some external piles können strangulate (called thrombosed piles), meaning they develop a Blutgerinnsel within them, causing pain, swelling, and sometimes bleeding. Infrared coagulation/photocoagulation This method of piles treatment uses infrared.
Weiterführende Lektüre und Referenzen
- coagulation factor II, thrombin; MedlinePlus, National Library of Medicine.
- Akhavan S, Mannucci PM, Lak M, Mancuso G, Mazzucconi MG, Rocino A, Jenkins PV, Perkins SJ. Identification and three-dimensional structural analysis of nine novel mutations in patients with prothrombin deficiency. Thromb Haemost. 2000 Dec;84(6):989-97.
- Danckwardt S, Hartmann K, Gehring NH, Hentze MW, Kulozik AE. 3' end processing of the prothrombin mRNA in thrombophilia. Acta Haematol. 2006;115(3-4):192-7. doi: 10.1159/000090934.
- Jayandharan G, Viswabandya A, Baidya S, Nair SC, Shaji RV, Chandy M, Srivastava A. Molecular genetics of hereditary prothrombin deficiency in Indian patients: identification of a novel Ala362 --> Thr (Prothrombin Vellore 1) mutation. J Thromb Haemost. 2005 Jul;3(7):1446-53. doi: 10.1111/j.1538-7836.2005.01402.x.
- Kujovich JL. Prothrombin Thrombophilia. 2006 Jul 25 [updated 2021 Feb 4]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1148/
- McGlennen RC, Key NS. Clinical and laboratory management of the prothrombin G20210A mutation. Arch Pathol Lab Med. 2002 Nov;126(11):1319-25. doi: 10.5858/2002-126-1319-CALMOT.
- Spector EB, Grody WW, Matteson CJ, Palomaki GE, Bellissimo DB, Wolff DJ, Bradley LA, Prior TW, Feldman G, Popovich BW, Watson MS, Richards CS. Technical standards and guidelines: venous thromboembolism (Factor V Leiden and prothrombin 20210G >A testing): a disease-specific supplement to the standards and guidelines for clinical genetics laboratories. Genet Med. 2005 Jul-Aug;7(6):444-53. doi: 10.1097/01.gim.0000172641.57755.3a.
- Sun WY, Witte DP, Degen JL, Colbert MC, Burkart MC, Holmback K, Xiao Q, Bugge TH, Degen SJ. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7597-602. doi: 10.1073/pnas.95.13.7597.
- Varga EA, Moll S. Cardiology patient pages. Prothrombin 20210 mutation (factor II mutation). Circulation. 2004 Jul 20;110(3):e15-8. doi: 10.1161/01.CIR.0000135582.53444.87. No abstract available.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
14. Jan 2025 | Neueste Version
1 Jan 2025 | Ursprünglich veröffentlicht
Teilen Sie Ihre Gedanken oder Erfahrungen mit anderen in unserem Patientengemeinschaften.
Abonnieren Sie den Patienten-Newsletter
Ihre wöchentliche Dosis klarer, vertrauenswürdiger Gesundheitsberatung - geschrieben, um Ihnen zu helfen, sich informiert, selbstbewusst und in Kontrolle zu fühlen.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.

